A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma.
A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma.
复制标题
儿童期化疗方案可提高 T 淋巴细胞淋巴瘤成人患者的总体生存率。
DOI：
10.18632/oncotarget.9144
复制
发表时间：
2016-06-21
期刊：
影响因子：
--
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Zhu MY;Wang H;Huang CY;Xia ZJ;Chen XQ;Geng QR;Wang WD;Wang L;Lu Y
成人T淋巴母细胞淋巴瘤（T-LBL）的广泛接受的标准治疗尚未确定。为了解决这个问题，我们回顾性地比较了三种化疗方案用于治疗110例新诊断的T-LBL成人患者。其中包括两种成人方案（ECOG 2993和hyper-CVAD）和一种儿童方案（BFM-90）。这些强化药物方案主要用于治疗儿童和成人急性淋巴细胞白血病。他们包括诱导，巩固和维持化疗方案，并在2年的过程中管理。75例患者（80%）达到完全缓解（CR）。中位随访时间为31个月（范围：5-152个月），5年总生存期（OS）和无进展生存期（PFS）率分别为47.7%（95% CI，35.0-69.8%）和45.7%（95% CI，27.6-56.6%）。生存期短与年龄> 40岁、ECOG PS差和骨髓受累相关。乳酸脱氢酶（LDH）水平升高、安阿伯分期和国际预后指数（IPI）评分无预后价值。儿童期化疗方案对< 40岁患者的CR和总生存率的改善优于成人期化疗方案。
A broadly accepted standard treatment for adult T-lymphoblastic lymphoma (T-LBL) has not yet been defined. To address that issue, we retrospectively compared three chemotherapy regimens used to treat 110 adult patients with newly diagnosed T-LBL. These included two adult regimens (ECOG2993 and hyper-CVAD) and a childhood regimen (BFM-90). These intensive drug regimens are mainly used to treat childhood and adult acute lymphoblastic leukemia. They included induction, consolidation, and maintenance chemotherapy protocols and were administered over the course of 2 years. Seventy-five patients (80%) achieved a complete remission (CR). Within a median follow-up time of 31 months (range: 5–152 months), the 5-year overall survival (OS) and progression-free survival (PFS) rates were 47.7% (95% CI, 35.0–69.8%) and 45.7% (95% CI, 27.6–56.6%), respectively. Shorter survival was associated with age > 40 years, poor ECOG PS and bone marrow involvement. Elevated lactic dehydrogenase (LDH) level, Ann Arbor stage and International Prognostic Index (IPI) score had no prognostic value. The childhood chemotherapy regimen improved CR and the overall survival rate more than the adult regimen in patients aged < 40 years.
登录
查看更多内容
影响因子：
20.3
作者：
Thomas, DA;O'Brien, S;Kantarjian, H
通讯作者：
Kantarjian, H
影响因子：
45.3
作者：
SLATER, DE;MERTELSMANN, R;CLARKSON, BD
通讯作者：
CLARKSON, BD
影响因子：
2.6
作者：
COLGAN, JP;ANDERSEN, J;GLICK, JH
通讯作者：
GLICK, JH
影响因子：
45.3
作者：
MOREL, P;LEPAGE, E;GISSELBRECHT, C
通讯作者：
GISSELBRECHT, C
影响因子：
158.5
作者：
SHIPP, MA;HARRINGTON, DP;YEAP, BY
通讯作者：
YEAP, BY